Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, including diabetes, cancer, cardiovascular, renal, and other diseases. The company’s product portfolio includes covasc, crystorvas, and vytocor; lebreta, and krabeva; and unihepa, erysaa, bi-haemosol, and haemosol. In addition, it offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, IRORO Nutreatment, and Uphamol brands. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is based in Klang, Malaysia.
Metrics to compare | DUOP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDUOPPeersSector | |
---|---|---|---|---|
P/E Ratio | 17.7x | 22.4x | −0.5x | |
PEG Ratio | 0.30 | −0.71 | 0.00 | |
Price/Book | 1.8x | 1.9x | 2.6x | |
Price / LTM Sales | 1.5x | 2.1x | 3.2x | |
Upside (Analyst Target) | 24.1% | 13.9% | 41.2% | |
Fair Value Upside | Unlock | 13.6% | 6.2% | Unlock |